Sign In
Buy NVCR
$14.84
-0.390 (-2.56%)
At Close: Jul 31, 2026
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 27'th Jul 2026
NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade
11:03am, Monday, 27'th Jul 2026
The mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects
10:29am, Monday, 27'th Jul 2026
Examine the evolution of NovoCure's (NVCR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
NovoCure: Why I'm Fading The Q2 Earnings Rally
01:45pm, Friday, 24'th Jul 2026
NovoCure remains a Hold as recent gains and operational improvements do not alter its long-term, glioblastoma-centric outlook. Q2 revenue grew 16% Y/Y to $183.6M, with adjusted EBITDA guidance raised
NovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)
10:21am, Friday, 24'th Jul 2026
Novocure (NVCR) delivered a strong 2Q26 beat, raising full-year guidance to $710–$725 million and achieving positive adjusted EBITDA, signaling a credible path to profitability. NVCR's operating lev
NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcript
01:00pm, Thursday, 23'rd Jul 2026
NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcript
NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates
09:16am, Thursday, 23'rd Jul 2026
NovoCure (NVCR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.36 per share a year ago.
NovoCure Q2 Earnings Call Highlights
09:08am, Thursday, 23'rd Jul 2026
NovoCure NASDAQ: NVCR reported record second-quarter 2026 net revenue and active patient levels, with management pointing to growth across its approved products and improved expense discipline as it r
Novocure Reports Second Quarter 2026 Financial Results
08:00am, Thursday, 23'rd Jul 2026
Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to exte
Novocure Reports Second Quarter 2026 Financial Results
07:00am, Thursday, 23'rd Jul 2026
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend su
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:06am, Thursday, 16'th Jul 2026
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
10:00am, Thursday, 16'th Jul 2026
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to c
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
06:24pm, Tuesday, 14'th Jul 2026
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are ad
NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026
03:01pm, Friday, 10'th Jul 2026
NovoCure Limited is downgraded from Strong Buy to Buy after the phase 3 TRIDENT trial failed to meet its primary endpoint of OS in newly diagnosed GBM patients. Company maintains growth potential with
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
05:40pm, Thursday, 09'th Jul 2026
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to co
